MRK - AbCellera Biologics: The COVID Premium Is Gone Thanks To Merck - Time To Buy

• AbCellera shares have been rocked by news of Merck's "COVID pill" treatment, sending shares down 25% from recent highs.
• In September, AbCellera's current antibody therapy was put back into use after an FDA pause, giving the company back a key revenue source.
• The company's pan variant Bebetelovimab therapy readout is expected soon and could provide a long-term revenue source for years to come.
• The COVID-19 therapies are a nice bonus, but my interest in AbCellera is not predicated on these therapies' success; therefore, with the premium for COVID seemingly largely out of the stock, I have begun to accumulate shares again.

For further details see: